BHCM
CYTK icon

Boulder Hill Capital Management’s Cytokinetics CYTK Stock Holding History

Boulder Hill Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-11,400
Closed -$522K – 152
2022
Q4 		$522K Buy
+11,400
New +$491K 0.43% 56

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Boulder Hill Capital Management's CYTK Position: Q1 2023 in Review

Boulder Hill Capital Management sold out of Cytokinetics (CYTK) in Q1 2023, closing a stake of 11,400 shares — an estimated $522K sold.

Boulder Hill Capital Management first reported a position in CYTK in Q4 2022 and held it in 1 quarter. The position peaked at $522K in Q4 2022. 262 funds tracked by Wall St. Rank hold CYTK as of Q1 2023.

  • Boulder Hill Capital Management reported no remaining Cytokinetics position as of Q1 2023 after selling out during the quarter.
  • Boulder Hill Capital Management sold 11,400 Cytokinetics shares in Q1 2023, an estimated $522K.
  • Boulder Hill Capital Management first reported a position in Cytokinetics in Q4 2022 and held it in 1 quarter.
  • Boulder Hill Capital Management's Cytokinetics position peaked at $522K in Q4 2022.
  • 262 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2023.

Based on Boulder Hill Capital Management's 13F filing for Q1 2023, filed 12 May 2023.